Stocks in play: Oncolytics Biotech Inc
Today issued a corporate update to provide investors with a deeper understanding of recent data and what is expected for 2025. Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval. Key milestones in gastrointestinal cancer clinical trials are expected in 2025, with potential for new registration-enabling studies. Oncolytics Biotech Inc shares T.ONC are trading up $0.07 at $1.27.
Read:
Energy Storage and Battery Tech Set to Lead the Future of Green Energy Innovation
Gold and Silver Miners Reap Rewards as Metal Prices Reach New Highs
DOE Injects Billions into Battery Recycling in Response to Growing EV Market Developments
How AI and Quantum Computing Are Transforming Security in 2024 and Beyond
AI in Healthcare Set for Explosive Growth with Projections Hitting $613 Billion by 2034